
Monoclonal Antibody Bentracimab Shown to Reverse Antiplatelet Effect of Brilinta | ACC 2025
Bentracimab, a monoclonal antibody administered intravenously, can be an effective agent to quickly reverse the effects of the antiplatelet agent Brilinta (ticagrelor) in patients who need to have urgent surgery or who are having major bleeding, a study …